BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Pharm Country

  Otsuka to Host Web Briefing on Tolvaptan Phase III Trial Results in Polycystic Kidney Disease

  Otsuka Pharmaceutical Co. and its affiliate Otsuka Pharmaceutical Development & Commercialization are pleased to invite investors and media to a November 4 web briefing on in-depth results from the REPRISE phase 3 trial for tolvaptan

  October 27, 2017

   · 

  3 min read
• Drug Development

  ORIC Pharma Announces First Subject Dosed in Phase I Clinical Study of Novel GR Antagonist with Planned Development for Oncology

  ORIC Pharma announced today that the first subject in a Phase Ia clinical study has been dosed with ORIC-101, a potent small molecule inhibitor of the glucocorticoid receptor.

  October 27, 2017

   · 

  2 min read
• 

  Business

  Zynex Growth Leads to a New Corporate HQ

  Zynex will be moving its corporate headquarters to 9555 Maroon Circle, Englewood CO 80112.

  October 27, 2017

   · 

  2 min read
• BioMidwest

  ACIST Medical Systems Announces Approval and Launch of Next-Generation FFR System

  The RXi Mini System will debut at the 29th Transcatheter Cardiovascular Therapeutics scientific symposium in Denver, Colorado.

  October 27, 2017

   · 

  3 min read
• Biotech Beach

  PharmaCyte Biotech Update on Shareholder Call

  Mr. Waggoner will also report on the progress being made by PharmaCyte in its diabetes program and ascites program.

  October 27, 2017

   · 

  3 min read
• Genetown

  Unum Therapeutics to Present New Data on Its Antibody-Coupled T Cell Receptor (ACTR) Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  Unum Therapeutics announced that the Company will be presenting on its Antibody-Coupled T cell Receptor (ACTR) platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held in Philadelphia, PA on October 27-30, 2017.

  October 27, 2017

   · 

  3 min read
• Genetown

  Treatment Effects Maintained Over Five Years in Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme’s Lemtrada (Alemtuzumab) in Extension Study After Switching from Interferon Beta-1a

  These investigational data are being presented during the 7th Joint Meeting of the European and Americas Committees for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS).

  October 27, 2017

   · 

  15 min read
• Drug Development

  Epizyme Presents Data from a Phase I Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  First presentation of pediatric dose escalation data in tazemetostat, showing favorable safety and tolerability with promising anti-tumor activity.

  October 27, 2017

   · 

  6 min read
• Pharm Country

  Celsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock

  The closing of this offering is expected to take place on or about October 31, 2017.

  October 27, 2017

   · 

  3 min read
• Drug Development

  Anavex Life Sciences Announces New Data Related to Multiple Sclerosis

  The data was presented in an oral presentation by the lead investigator, Robert Lisak, MD.

  October 27, 2017

   · 

  4 min read